A platform of assays for the discovery of anti-Zika small-molecules with activity in a 3D-bioprinted outer-blood-retina model.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 09 04 2021
accepted: 10 12 2021
entrez: 18 1 2022
pubmed: 19 1 2022
medline: 17 2 2022
Statut: epublish

Résumé

The global health emergency posed by the outbreak of Zika virus (ZIKV), an arthropod-borne flavivirus causing severe neonatal neurological conditions, has subsided, but there continues to be transmission of ZIKV in endemic regions. As such, there is still a medical need for discovering and developing therapeutical interventions against ZIKV. To identify small-molecule compounds that inhibit ZIKV disease and transmission, we screened multiple small-molecule collections, mostly derived from natural products, for their ability to inhibit wild-type ZIKV. As a primary high-throughput screen, we used a viral cytopathic effect (CPE) inhibition assay conducted in Vero cells that was optimized and miniaturized to a 1536-well format. Suitably active compounds identified from the primary screen were tested in a panel of orthogonal assays using recombinant Zika viruses, including a ZIKV Renilla luciferase reporter assay and a ZIKV mCherry reporter system. Compounds that were active in the wild-type ZIKV inhibition and ZIKV reporter assays were further evaluated for their inhibitory effects against other flaviviruses. Lastly, we demonstrated that wild-type ZIKV is able to infect a 3D-bioprinted outer-blood-retina barrier tissue model and disrupt its barrier function, as measured by electrical resistance. One of the identified compounds (3-Acetyl-13-deoxyphomenone, NCGC00380955) was able to prevent the pathological effects of the viral infection on this clinically relevant ZIKV infection model.

Identifiants

pubmed: 35041689
doi: 10.1371/journal.pone.0261821
pii: PONE-D-21-11785
pmc: PMC8765781
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0261821

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Bioorg Med Chem Lett. 2020 Mar 1;30(5):126965
pubmed: 31980339
Methods. 2008 Jan;44(1):31-8
pubmed: 18158130
Rev Med Virol. 2006 Jan-Feb;16(1):37-48
pubmed: 16287208
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Antiviral Res. 2017 May;141:140-149
pubmed: 28232248
Microorganisms. 2020 Apr 20;8(4):
pubmed: 32326119
Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):31365-31375
pubmed: 33229545
J Biomol Screen. 1999;4(2):67-73
pubmed: 10838414
Pharmaceuticals (Basel). 2019 Jun 29;12(3):
pubmed: 31261947
Antiviral Res. 2018 May;153:85-94
pubmed: 29524445
PLoS Pathog. 2017 May 25;13(5):e1006411
pubmed: 28542603
ACS Infect Dis. 2020 May 8;6(5):909-915
pubmed: 32125140
J Nat Med. 2018 Sep;72(4):905-914
pubmed: 29961188
Adv Drug Deliv Rev. 2018 Jul;132:296-332
pubmed: 29990578
J Gen Virol. 1986 Sep;67 ( Pt 9):2017-22
pubmed: 3018134
Emerg Infect Dis. 2016 Aug;22(8):1438-44
pubmed: 27144515
Trans R Soc Trop Med Hyg. 1952 Sep;46(5):509-20
pubmed: 12995440
J Virol Methods. 2001 Mar;92(1):37-44
pubmed: 11164916
Nat Med. 2017 Jun;23(6):763-767
pubmed: 28394328
Biofabrication. 2020 Apr 09;12(3):035002
pubmed: 32059197
Antiviral Res. 2017 Mar;139:49-58
pubmed: 28034741
Int J Infect Dis. 2014 Jun;23:75-81
pubmed: 24704332
Antiviral Res. 2017 Jul;143:218-229
pubmed: 28461069
J Med Chem. 2006 Dec 14;49(25):7502-12
pubmed: 17149879
Phytochemistry. 2009 Jan;70(1):105-13
pubmed: 19091359
Antiviral Res. 2019 Nov;171:104590
pubmed: 31421166
J Vis Exp. 2014 Nov 04;(93):e52065
pubmed: 25407402
Viruses. 2018 May 14;10(5):
pubmed: 29758005
J Biol Res (Thessalon). 2020 Mar 4;27:5
pubmed: 32158705
Mol Neurobiol. 2012 Jun;45(3):586-95
pubmed: 22614130
Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618761299
pubmed: 29534608
Clin Transl Sci. 2018 Sep;11(5):461-470
pubmed: 29877628
Nat Rev Drug Discov. 2012 Dec;11(12):937-57
pubmed: 23197040
Phytochemistry. 2008 Feb;69(3):796-804
pubmed: 17936315
J Vis Exp. 2016 Aug 23;(114):
pubmed: 27584546
Oncol Lett. 2012 Jul;4(1):22-28
pubmed: 22807953
PLoS One. 2015 Jun 22;10(6):e0130062
pubmed: 26098995
Curr Top Med Chem. 2018;18(20):1792-1803
pubmed: 30465510
Front Immunol. 2018 May 03;9:821
pubmed: 29774022
J Virol. 2015 Sep;89(17):8880-96
pubmed: 26085147
ACS Cent Sci. 2018 Dec 26;4(12):1727-1741
pubmed: 30648156
Annu Rev Microbiol. 1990;44:649-88
pubmed: 2174669
Nat Commun. 2017 Jul 25;8:15672
pubmed: 28742068
JCI Insight. 2017 Feb 23;2(4):e92340
pubmed: 28239662
Antiviral Res. 2017 Mar;139:117-128
pubmed: 28049006
Nat Commun. 2017 Sep 22;8(1):676
pubmed: 28939807
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11473-8
pubmed: 16864780
Toxicol Appl Pharmacol. 1984 Jul;74(3):345-56
pubmed: 6740683
Lancet. 2016 Jun 25;387(10038):2599-2600
pubmed: 27353815
J Virol. 2017 Mar 29;91(8):
pubmed: 28148798
Assay Drug Dev Technol. 2008 Oct;6(5):637-57
pubmed: 19035846
BMJ. 2016 Feb 02;352:i657
pubmed: 26839247
Nature. 2016 Dec 15;540(7633):443-447
pubmed: 27819683
Cell Host Microbe. 2016 Aug 10;20(2):259-70
pubmed: 27476412
Science. 2016 Apr 22;352(6284):467-70
pubmed: 27033547
JALA Charlottesv Va. 2008 Apr;13(2):79-89
pubmed: 18496600
Invest New Drugs. 2003 Nov;21(4):413-20
pubmed: 14586208
Nat Microbiol. 2020 Jun;5(6):796-812
pubmed: 32367055
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30061280
Cell Stem Cell. 2016 Nov 3;19(5):672
pubmed: 27814481
J Infect Dis. 2016 Sep 1;214(5):707-11
pubmed: 27234417
Neurotherapeutics. 2017 Oct;14(4):1027-1048
pubmed: 28952036
Nat Med. 2016 Oct;22(10):1101-1107
pubmed: 27571349
EBioMedicine. 2018 Oct;36:92-102
pubmed: 30201444
Chem Biodivers. 2010 Oct;7(10):2327-580
pubmed: 20963775
Drug Discov Today. 2018 Nov;23(11):1833-1847
pubmed: 29935345
Cell Host Microbe. 2016 Jun 8;19(6):891-900
pubmed: 27198478
Science. 2015 Apr 17;348(6232):282-3
pubmed: 25883340
Sci Rep. 2018 Jul 25;8(1):11209
pubmed: 30046058
Front Microbiol. 2019 Dec 06;10:2725
pubmed: 31866959
J Virol. 2019 Aug 28;93(18):
pubmed: 31270223
Adv Exp Med Biol. 2019;1186:171-193
pubmed: 31654390
Cell Rep. 2017 Jan 17;18(3):804-815
pubmed: 28099856
Microbiol Mol Biol Rev. 2017 Feb 8;81(1):
pubmed: 28179396
Viruses. 2016 Nov 29;8(12):
pubmed: 27916837
Neuron. 2016 Dec 7;92(5):949-958
pubmed: 27930910
J Virol. 2018 Jan 30;92(4):
pubmed: 29212931
World J Virol. 2018 Feb 12;7(1):10-20
pubmed: 29468137
Virus Res. 2018 Jan 15;244:64-70
pubmed: 29113824
Biomed Pharmacother. 2020 Jul;127:110198
pubmed: 32559845
Ann Intern Med. 2016 May 17;164(10):689-91
pubmed: 26914810
J Leukoc Biol. 2013 May;93(5):801-10
pubmed: 23463725
Cell. 2016 May 19;165(5):1081-1091
pubmed: 27180225
J Gen Virol. 1991 Apr;72 ( Pt 4):851-8
pubmed: 1826736

Auteurs

Dorjbal Dorjsuren (D)

Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States of America.

Richard T Eastman (RT)

Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States of America.

Min Jae Song (MJ)

Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States of America.

Adam Yasgar (A)

Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States of America.

Yuchi Chen (Y)

Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States of America.

Kapil Bharti (K)

Unit on Ocular and Stem Cell Translational Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States of America.

Alexey V Zakharov (AV)

Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States of America.

Ajit Jadhav (A)

Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States of America.

Marc Ferrer (M)

Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States of America.

Pei-Yong Shi (PY)

University of Texas Medical Branch Galveston, Galveston, TX, United States of America.

Anton Simeonov (A)

Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH